An Initial Analysis of the Baseline Levels of Dd-cfDNA After Pancreas Transplantation : A Prospective Study From High-volume Centers in the United States
Copyright © 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc..
Pancreas transplantation offers patients with diabetes an opportunity for glucose homeostasis. Current blood tests to surveil for rejection have poor sensitivity and specificity for identifying rejection, and pancreas biopsies are challenging and associated with morbidity and graft loss. Donor-derived cell-free DNA (dd-cfDNA) is shed from transplanted organs and detectable in peripheral blood. Thus, a potential dd-cfDNA blood test assessing rejection would be clinically advantageous.
Methods: One hundred eighty-one dd-cfDNA samples (n) were collected from 77 patients (N) up to 132 mo posttransplant.
Results: The median dd-cfDNA level among all subjects was 0.28% (0.13%, 0.71%). In simultaneous pancreas-kidney (SPK) transplant recipients, the median dd-cfDNA level was 0.29% (0.13%, 0.71%), and it was 0.23% (0.08%, 0.71%) in pancreas transplant alone (PTA) recipients. When isolating for when without infection or rejection, the median dd-cfDNA level was 0.28% (0.13%, 0.64%) for SPK and 0.20% (0.00%, 0.32%) for PTA. Both transplant types approached 1.0% ≤1 mo posttransplant followed by a decrease in median dd-cfDNA. During episodes of rejection or infection, median dd-cfDNA levels were greater among all transplant types.
Conclusions: The mean dd-cfDNA level for all pancreas transplant recipients is <1.0%, consistent with the published kidney transplant rejection threshold (>1.0%), regardless of SPK or PTA. Early posttransplant dd-cfDNA levels are transiently higher than later measurements. Dd-cfDNA elevation also correlates with rejection and infection and thus is a promising biomarker for surveilling pancreas transplant dysfunction.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Transplantation direct - 9(2023), 4 vom: 10. Apr., Seite e1459 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoo, Ashley [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 21.03.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1097/TXD.0000000000001459 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354412558 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354412558 | ||
| 003 | DE-627 | ||
| 005 | 20231226062151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/TXD.0000000000001459 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354412558 | ||
| 035 | |a (NLM)36935870 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoo, Ashley |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Initial Analysis of the Baseline Levels of Dd-cfDNA After Pancreas Transplantation |b A Prospective Study From High-volume Centers in the United States |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a Pancreas transplantation offers patients with diabetes an opportunity for glucose homeostasis. Current blood tests to surveil for rejection have poor sensitivity and specificity for identifying rejection, and pancreas biopsies are challenging and associated with morbidity and graft loss. Donor-derived cell-free DNA (dd-cfDNA) is shed from transplanted organs and detectable in peripheral blood. Thus, a potential dd-cfDNA blood test assessing rejection would be clinically advantageous | ||
| 520 | |a Methods: One hundred eighty-one dd-cfDNA samples (n) were collected from 77 patients (N) up to 132 mo posttransplant | ||
| 520 | |a Results: The median dd-cfDNA level among all subjects was 0.28% (0.13%, 0.71%). In simultaneous pancreas-kidney (SPK) transplant recipients, the median dd-cfDNA level was 0.29% (0.13%, 0.71%), and it was 0.23% (0.08%, 0.71%) in pancreas transplant alone (PTA) recipients. When isolating for when without infection or rejection, the median dd-cfDNA level was 0.28% (0.13%, 0.64%) for SPK and 0.20% (0.00%, 0.32%) for PTA. Both transplant types approached 1.0% ≤1 mo posttransplant followed by a decrease in median dd-cfDNA. During episodes of rejection or infection, median dd-cfDNA levels were greater among all transplant types | ||
| 520 | |a Conclusions: The mean dd-cfDNA level for all pancreas transplant recipients is <1.0%, consistent with the published kidney transplant rejection threshold (>1.0%), regardless of SPK or PTA. Early posttransplant dd-cfDNA levels are transiently higher than later measurements. Dd-cfDNA elevation also correlates with rejection and infection and thus is a promising biomarker for surveilling pancreas transplant dysfunction | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Riedel, Alexandria |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Bartosic, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Soltani, Rudi |e verfasserin |4 aut | |
| 700 | 1 | |a Kibria, Gulam |e verfasserin |4 aut | |
| 700 | 1 | |a Haririan, Abdolreza |e verfasserin |4 aut | |
| 700 | 1 | |a Drachenberg, Cinthia B |e verfasserin |4 aut | |
| 700 | 1 | |a Abrams, Peter L |e verfasserin |4 aut | |
| 700 | 1 | |a Odorico, Jon S |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Bromberg, Jonathan S |e verfasserin |4 aut | |
| 700 | 1 | |a Scalea, Joseph R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation direct |d 2015 |g 9(2023), 4 vom: 10. Apr., Seite e1459 |w (DE-627)NLM249149893 |x 2373-8731 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:4 |g day:10 |g month:04 |g pages:e1459 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/TXD.0000000000001459 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 4 |b 10 |c 04 |h e1459 | ||